544 related articles for article (PubMed ID: 30078086)
1. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
van der Heijde D; Durez P; Schett G; Naredo E; Østergaard M; Meszaros G; De Leonardis F; de la Torre I; López-Romero P; Schlichting D; Nantz E; Fleischmann R
Clin Rheumatol; 2018 Sep; 37(9):2381-2390. PubMed ID: 30078086
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN.
López-Romero P; Martinez-Gamboa L; Bang H; de la Torre I; Holzkämper T; Feist E
Arthritis Res Ther; 2020 Aug; 22(1):193. PubMed ID: 32811536
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
Fleischmann R; Takeuchi T; Schiff M; Schlichting D; Xie L; Issa M; Stoykov I; Lisse J; Martinez-Osuna P; Rooney T; Zerbini CAF
Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1112-1121. PubMed ID: 31233281
[TBL] [Abstract][Full Text] [Related]
6. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
[TBL] [Abstract][Full Text] [Related]
10. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
[TBL] [Abstract][Full Text] [Related]
12. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
13. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
van der Heijde D; Kartman CE; Xie L; Beattie S; Schlichting D; Mo D; Durez P; Tanaka Y; Fleischmann R
J Rheumatol; 2022 Feb; 49(2):133-141. PubMed ID: 34526397
[TBL] [Abstract][Full Text] [Related]
14. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
[TBL] [Abstract][Full Text] [Related]
17. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.
Taylor PC; Alten R; Álvaro Gracia JM; Kaneko Y; Walls C; Quebe A; Jia B; Bello N; Terres JR; Fleischmann R
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35264432
[TBL] [Abstract][Full Text] [Related]
18. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
[TBL] [Abstract][Full Text] [Related]
20. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
